UK's Redx Pharma rises 6% on Merck deal
16/12/2022 15:53
** Shares of UK's biotech firm Redx Pharma REDX.L rises 6%
** Redx signs clinical trial collaboration and supply
agreement with U.S.-listed Merck & Co MRK.N for the supply of
therapy drug Keytruda
** Keytruda to be used in the combination arm of Redx's
ongoing PORCUPINE2 Phase 2 clinical study into potential
treatment for patients with biliary cancer
** Biliary cancer is a type of cancer that forms in the bile
ducts inside the liver
** Including session's gain, stock down ~29% YTD
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((sruthinarasimha.chari@thomsonreuters.com))